Emergent BioSolutions, Inc. (EBS)
6.235
-0.22
(-3.48%)
USD |
NYSE |
Sep 03, 16:00
6.235
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Cash from Investing (Quarterly) : -52.30M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.30M |
| March 31, 2026 | -2.40M |
| December 31, 2025 | -3.90M |
| September 30, 2025 | -3.40M |
| June 30, 2025 | 17.20M |
| March 31, 2025 | 59.50M |
| December 31, 2024 | 28.60M |
| September 30, 2024 | 112.00M |
| June 30, 2024 | -4.60M |
| March 31, 2024 | -10.80M |
| December 31, 2023 | -11.40M |
| September 30, 2023 | -18.90M |
| June 30, 2023 | 257.70M |
| March 31, 2023 | -15.10M |
| December 31, 2022 | -45.40M |
| September 30, 2022 | -271.60M |
| June 30, 2022 | -32.10M |
| March 31, 2022 | -32.20M |
| December 31, 2021 | -45.80M |
| September 30, 2021 | -55.20M |
| June 30, 2021 | -67.00M |
| March 31, 2021 | -56.10M |
| December 31, 2020 | -36.00M |
| September 30, 2020 | -45.70M |
| June 30, 2020 | -45.10M |
| Date | Value |
|---|---|
| March 31, 2020 | -24.20M |
| December 31, 2019 | -36.10M |
| September 30, 2019 | -15.30M |
| June 30, 2019 | -24.10M |
| March 31, 2019 | -21.40M |
| December 31, 2018 | -848.55M |
| September 30, 2018 | -26.06M |
| June 30, 2018 | -10.98M |
| March 31, 2018 | -11.62M |
| December 31, 2017 | -207.55M |
| September 30, 2017 | -12.78M |
| June 30, 2017 | -9.301M |
| March 31, 2017 | -20.30M |
| December 31, 2016 | -20.01M |
| September 30, 2016 | -17.00M |
| June 30, 2016 | -21.03M |
| March 31, 2016 | -18.21M |
| December 31, 2015 | -11.83M |
| September 30, 2015 | -13.95M |
| June 30, 2015 | -10.60M |
| March 31, 2015 | -9.082M |
| December 31, 2014 | -17.26M |
| September 30, 2014 | -5.221M |
| June 30, 2014 | -4.81M |
| March 31, 2014 | -182.76M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Exelixis, Inc. | 91.43M |
| Capricor Therapeutics, Inc. | -48.76M |
| ADMA Biologics, Inc. | -2.256M |
| Akebia Therapeutics, Inc. | -4.079M |
| Arcutis Biotherapeutics, Inc. | -15.22M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 56.10M |
| Cash from Financing (Quarterly) | -24.40M |
| Free Cash Flow | 85.90M |
| Free Cash Flow Per Share (Quarterly) | 1.046 |
| Free Cash Flow to Equity (Quarterly) | 100.80M |
| Free Cash Flow to Firm (Quarterly) | 64.84M |
| Free Cash Flow Yield | 25.40% |